He said the drugs remain a "rational choice" for patients at low risk of cardiovascular problems who have had serious gastrointestinal events (such as bleeding), but he said it would "seem prudent" to avoid them with patients who have or are at risk of cardiovascular disease.When the recall occurred, it came about because of a major clinical study sponsored by Merck that tracked 2,600 patients for almost three years to find out if Vioxx helped prevent colon polyps.In a separate report released by the New England Journal, Dr. Eric Topol of the Cleveland Clinic chastises the FDA for not requiring Merck to do studies investigating heart problems with Vioxx when hints of them first appeared years ago.Studies done five years ago when Celebrex and Merck &amp; Co.'s Vioxx were approved suggest that the same mechanism that inhibits inflammation and makes the drugs easier on the stomach than traditional painkillers also blocks a substance that prevents heart problems, according to Dr. Garret FitzGerald, a University of Pennsylvania cardiologist.Neaton immediately called Baron, who was conducting the trial with a grant from Merck, and explained the problem.The issue of drug advertising directly aimed at consumers was thrust into the news recently when Merck withdrew its arthritis painkiller Vioxx from the market, citing studies indicating a risk of heart attacks or strokes.The Food and Drug Administration silenced one of its drug experts who raised safety concerns weeks before Merck &amp; Co. yanked the blockbuster drug Vioxx due to increased risks for heart attack and strokes, the chairman of the Senate Finance Committee said ThursMerck officials said last week its latest research showed an increased risk of heart attack and other cardiovascular complications in patients who took Vioxx for at least 18 months.The FDA could help solve these problems not only by enforcing its own rules but by requiring doctors and hospitals to report ``adverse events'' when patients use drugs.When Merck voluntarily withdrew Vioxx, FDA officials said heart problems were unique to that drug and that the mechanism underlying them wasn't known.Studies done five years ago when Pfizer's Celebrex and Merck &amp; Co.'s Vioxx were approved suggest the same mechanism that inhibits inflammation and makes them easier on the stomach than traditional painkillers also blocks a substance that prevents heart problems, according to Dr. Garret FitzGerald, chairman of pharmacology at the University of PennsylvanOver the past two weeks The Washington Post had interviewed independent researchers who collected and reviewed the Vioxx data, company officials who decided how Merck would respond, critics of the drug industry and regulators who, in the end, played almost no role in its recall.The controversy grew Friday when Grassley asked Merck, among other things, about an e-mail provided by Graham in which a Merck official complained that the FDA had not lived up to a prior agreement to alert the company before releasing any negative information about its products.The second article in the medical journal, by Dr. Eric Topol of the Cleveland Clinic, criticizes the FDA for not requiring Merck to do studies investigating heart problems with Vioxx even though hints of danger appeared years ago.Merck &amp; Co. removed Vioxx from use Thursday after new study results showed increased risk of heart attacks and stroke in people who used it for longer than 18 monIn a separate report also released by the medical journal, Dr. Eric Topol of the Cleveland Clinic chastises the FDA for not requiring Merck to do studies investigating heart problems with Vioxx when hints of them first appeared years ago, and for allowing the company to blitz consumers with TV ads touting the drug.